The inaugural stop of the “Yixin Cup” medical‑device innovation competition kicked off in Xiamen, marking a milestone for China’s high‑end health‑tech sector under the new 15th Five‑Year Plan. The event follows a historic breakthrough: the National Medical Products Administration approved the world’s first implantable brain‑computer interface system, signaling that Chinese firms are moving from research labs to real‑world clinics. Organised by the Shanghai Yangtze River Delta Business Innovation Research Institute, the Shanghai Yangtze River Delta Medical Innovation Life‑Health Industry Foundation and the China Medical Equipment Association, the competition opens four tracks – minimally invasive and implantable devices, smart hardware, rehabilitation and home‑care tools, and digital‑health solutions. More than 370 projects have already registered, with 68 % stemming from hospitals or research institutes and over 80 % backed by patents, showing strong clinical‑engineering integration. A full‑cycle support system – from screening and evaluation to awards, incubation, investment and production – links innovators with CROs, industrial bases, investors and local governments, creating a “green channel” for rapid market entry. The Xiamen launch aims to energise the West Coast of the Taiwan Strait, while subsequent city rounds remain open for nationwide participation. The competition promises to turn promising ideas into market‑ready medical breakthroughs, accelerating China’s shift from follower to leader in advanced medical devices.
Read moreA wave of stem‑cell discoveries is reshaping Chinese medicine in 2025. Researchers have finally pinpointed how mesenchymal stromal cells (MSCs) calm inflammation: they shrink a special group of immune cells called MX1‑positive monocytes, with the strongest effect a week after infusion. This insight could turn MX1 levels into a simple test for predicting patient response and guide repeat‑dose schedules. In a landmark diabetes study, Professor Deng Hongkui’s team coaxed human pluripotent stem cells into fully functional pancreatic islets that contain all five hormone‑producing cell types. In mouse models of type‑1 diabetes, these “reconstructed islets” not only regulated blood sugar but also prevented dangerous lows, thanks to the added alpha and delta cells. Meanwhile, a Phase II trial led by Sun Yat‑sen University injected umbilical‑cord MSCs into knees of osteoarthritis patients, marking the first multi‑center Chinese study of its kind. Early results suggest reduced pain and improved joint function. Long‑term data from Academician Wang Fusheng show MSC therapy lifts five‑year survival for decompensated liver cirrhosis by nearly 15 % and cuts complications. Parallel trials are now testing the same approach for acute‑on‑chronic liver failure. China also launched its first domestically produced stem‑cell drug, priced at about 20,000 RMB per bag—roughly one‑tenth of the U.S. equivalent—benefiting over 100 patients across 20 provinces. Finally, Yuesheng Biosciences presented six‑month follow‑up results for UX‑001, an autologous cell therapy for Parkinson’s disease, earning a spotlight at the International Parkinson’s Conference in Hawaii. Together, these advances signal a new era of precise, affordable regenerative medicine in China.
Read more